https://www.gosh.nhs.uk/our-research/our-research-infrastructure/nihr-great-ormond-street-hospital-brc/brc-news/autolus-acquires-rights-commercialise-novel-t-cell-therapy-developed-gosh-and-uclh/
Autolus acquires rights to commercialise novel T-cell therapy developed at GOSH and UCLH
24 Apr 2018, 2:56 p.m.
The biopharmaceutical company Autolus has acquired global rights to develop and commercialize a novel T-cell therapy for the treatment of B-cell lymphomas and leukaemias.The biopharmaceutical company Autolus has acquired global rights to develop and commercialize a novel T-cell therapy for the treatment of B-cell lymphomas and leukaemias. The therapy, known as AUTO1, is currently the subject of two Phase 1 studies: one in paediatric acute lymphoblastic leukaemia (ALL) led by National Institute for Health Research (NIHR) GOSH Biomedical Research Centre (BRC) researcher Professor Persis Amrolia and the other in adult ALL led by Dr Martin Pule at UCL Hospital (UCLH).
Autolus Limited specialises in developing next-generation programmed T-cell therapies and has acquired the rights from UCL Business plc (UCLB), the technology-transfer company of University College London (UCL).
The AUTO1 therapy uses a type of immune cell (T-cells) that have been modified to efficiently recognize and kill cancer cells. The T cells are engineered to express a novel CD19-specific chimeric antigen receptor (CAR), which targets B-cell lymphomas and leukaemia expressing the CD19 protein. AUTO1 is also designed to reduce the risk of cytokine release syndrome - a serious and potentially life-threatening side effect of immunotherapy. In the paediatric ALL study, which was recently presented at the the 2017 Annual Meeting of the American Society of Hematology, investigators observed levels of efficacy similar to those in other reported studies without the need to administer immunosuppressive drugs.
This partnership between UCL Business and Autolus will support the continued development of this promising approach and bring this ground-breaking new treatment one step closer to patients.
Read more: Autolus press release
Professor Waseem Qasim named in list of leading global health leaders
Professor Waseem Qasim, Consultant at GOSH and Professor of Cell and Gene Therapy at University College London has been named in TIME magazine’s 2026 TIME100 Health List of the World’s Most Influential Leaders in Health.
Alyssa Tapley named in list of leading global health leaders
GOSH patient, Alyssa Tapley, 17 from Leicester, has been named in TIME’S 2026 TIME100 Health List of the World’s Most Influential Leaders in Health.
GOSH joins partnership to boost early diagnosis and deliver better treatments
GOSH is partnering with LifeArc to set up KidsRare - a new initiative to help deliver more tests and treatments for children living with a rare disease.
How linked health and education data is changing what we know about children with neurodisability
Children with neurodisability often have complex health and educational needs, but population level data on long term outcomes remains limited. New research from GOS-ICH addresses this gap using one of the largest national birth cohorts to date.